Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The use of programmed cell death 1 ligand 1 (PD-L1) as a predictive biomarker to select patients to receive programmed cell death 1 (PD-1) or PD-L1 inhibitors in non-small cell lung cancer (NSCLC) is limited by the definitions of positivity, interassay agreement, and intra- and intertumoral heterogeneity of expression. Although PD-L1 expression enriches for responses, the lack of expression does not exclude clinical benefit.

Original languageEnglish (US)
Pages (from-to)220-222
Number of pages3
JournalClinical Pharmacology and Therapeutics
Volume100
Issue number3
DOIs
StatePublished - 2016

Fingerprint

CD274 Antigen
Non-Small Cell Lung Carcinoma
Immunotherapy
Patient Selection
Cell Death
Biomarkers

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{3d12099a6d66481a81e26fc64e7a4409,
title = "Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy",
abstract = "The use of programmed cell death 1 ligand 1 (PD-L1) as a predictive biomarker to select patients to receive programmed cell death 1 (PD-1) or PD-L1 inhibitors in non-small cell lung cancer (NSCLC) is limited by the definitions of positivity, interassay agreement, and intra- and intertumoral heterogeneity of expression. Although PD-L1 expression enriches for responses, the lack of expression does not exclude clinical benefit.",
author = "Aaron Mansfield and Dong, {Haidong M}",
year = "2016",
doi = "10.1002/cpt.360",
language = "English (US)",
volume = "100",
pages = "220--222",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy

AU - Mansfield, Aaron

AU - Dong, Haidong M

PY - 2016

Y1 - 2016

N2 - The use of programmed cell death 1 ligand 1 (PD-L1) as a predictive biomarker to select patients to receive programmed cell death 1 (PD-1) or PD-L1 inhibitors in non-small cell lung cancer (NSCLC) is limited by the definitions of positivity, interassay agreement, and intra- and intertumoral heterogeneity of expression. Although PD-L1 expression enriches for responses, the lack of expression does not exclude clinical benefit.

AB - The use of programmed cell death 1 ligand 1 (PD-L1) as a predictive biomarker to select patients to receive programmed cell death 1 (PD-1) or PD-L1 inhibitors in non-small cell lung cancer (NSCLC) is limited by the definitions of positivity, interassay agreement, and intra- and intertumoral heterogeneity of expression. Although PD-L1 expression enriches for responses, the lack of expression does not exclude clinical benefit.

UR - http://www.scopus.com/inward/record.url?scp=84988971695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988971695&partnerID=8YFLogxK

U2 - 10.1002/cpt.360

DO - 10.1002/cpt.360

M3 - Article

C2 - 26916808

AN - SCOPUS:84988971695

VL - 100

SP - 220

EP - 222

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -